Condition: Neurogenic Bowel (Disorder) · Fecal Constipation · Fecal Incontinence · Sponsor: Wellspect HealthCare
A randomized, superiority, controlled, interventional, prospective, multicentre, post-market study of TAI with Navina™ Smart versus Standard Bowel Care performed in a population of 92 subjects suffering from Multiple Sclerosis and confirmed Neurogenic Bowel Dysfunction. The study is expected to last for a total of 8 weeks per subject with two scheduled site visits.
This description comes directly from the study's public registry record.
Wellspect HealthCare · +46 31 376 40 00 · mace@wellspect.com
Always discuss trial participation with your own doctor first.
| Aarhus University Hospital | Aarhus, Denmark | Recruiting |
| Hospital Tenon Service de Neuro-urologie et d'Explorations Périnéales | Paris, France | Recruiting |
| Azienda Ospedaliero-Universitaria of Ferrara | Ferrara, Cona, Italy | Recruiting |
| AISM Liguria Rehabilitation Centre | Genoa, Liguria, Italy | Recruiting |
| AOU Careggi | Florence, Tuscany, Italy | Recruiting |
| Azienda Ospedaliero Universitaria Consorziale Policlinico con sede in Bari | Bari, Italy | Recruiting |
| La Fé University Hospital | Valencia, Spain | Recruiting |
| Centre Hospitalier Universitaire Vaudois (CHUV) | Lausanne, Switzerland | Withdrawn |
| University College London Hospital | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04707976